PCIA
TAK icon

Prime Capital Investment Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Prime Capital Investment Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-377
Closed -$7K – 486
2020
Q3 		$7K Hold
377
– – ﹤0.01% 412
2020
Q2 		$7K Hold
377
– – ﹤0.01% 432
2020
Q1 		$6K Buy
+377
New +$6.83K ﹤0.01% 427

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

Prime Capital Investment Advisors's TAK Position: Q4 2020 in Review

Prime Capital Investment Advisors sold out of Takeda Pharmaceutical (TAK) in Q4 2020, closing a stake of 377 shares — an estimated $7K sold.

Prime Capital Investment Advisors first reported a position in TAK in Q1 2020 and held it in 3 quarters. The position peaked at $7K in Q3 2020. 313 funds tracked by Wall St. Rank hold TAK as of Q4 2020.

  • Prime Capital Investment Advisors reported no remaining Takeda Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 377 Takeda Pharmaceutical shares in Q4 2020, an estimated $7K.
  • Prime Capital Investment Advisors first reported a position in Takeda Pharmaceutical in Q1 2020 and held it in 3 quarters.
  • Prime Capital Investment Advisors's Takeda Pharmaceutical position peaked at $7K in Q3 2020.
  • 313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2020.

Based on Prime Capital Investment Advisors's 13F filing for Q4 2020, filed 3 Feb 2021.